24 April 2026·PIB

IPC Signs MoUs with the Pharmaceuticals & Medical Devices Bureau of India and National Institute of Pharmaceuticals Education & Research, Hajipur, to Promote Drug Quality, Research, and Patient Safety

In this note

1. At a Glance

Indian Pharmacopoeia Commission (IPC) signed two MoUs — with Pharmaceuticals & Medical Devices Bureau of India (PMBI) and with NIPER, Hajipur (Bihar) — to advance drug quality, pharmacovigilance, pharmacopoeial research, and patient safety [1][2].
Relevant for UPSC under GS-II (Health, Government Policies) and GS-III (S&T, Pharma sector); tests aspirants on the institutional ecosystem of drug regulation in India.

On 24 April 2026, IPC (Ghaziabad), under the Ministry of Health & Family Welfare, signed two MoUs to (a) institutionalise quality assurance for Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) medicines through PMBI, and (b) deepen collaborative pharmaceutical research with NIPER Hajipur [1][2].

IPC — autonomous body under Ministry of Health & Family Welfare, located at Ghaziabad; publishes the Indian Pharmacopoeia (IP), the official book of drug standards [3][4].
IPC functions as the National Coordination Centre (NCC) for the Pharmacovigilance Programme of India (PvPI) [3].
10th Edition of Indian Pharmacopoeia released by Union Health Minister J.P. Nadda [4].
IPC pursuing recognition as the first WHO Collaborating Centre for Safety of Medicines and Vaccines in South-East Asia [5].
PMBI — implementing agency of PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.
NIPER Hajipur — one of seven NIPERs (institutes of national importance under NIPER Act, 1998).
IPC has earlier signed MoUs with State Pharmacy Councils of Bihar, Maharashtra, Mizoram, Nagaland, and Goa to expand pharmacovigilance reach [6][7].

Parent ministry (IPC): Ministry of Health & Family Welfare [1].
Parent ministry (PMBI/PMBJP): Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.
HQ: IPC – Ghaziabad; NIPER – Hajipur (Bihar).
Date of MoUs: 24 April 2026 [1].
IPC role under PvPI: runs Adverse Drug Reaction Monitoring System (ADRMS) — India's first indigenous medical product safety database [3].
Flagship publication: Indian Pharmacopoeia, currently in its 10th Edition [4].

Administrative / Governance

IPC–PMBI MoU operationalises random batch testing of Jan Aushadhi medicines at IPC labs, plugging a regulatory gap between procurement and quality verification [1].
Joint sensitisation/training of pharmacists on rational use of medicines, ADR reporting, pharmacovigilance [1].

Scientific / Technological

IPC–NIPER MoU targets impurity profiling, especially genotoxic nitrosamine impurities, correlated with ADR data to set evidence-based pharmacopoeial limits [1].
Research extends to biologics and emerging therapies [1].

Social / Public Health

Strengthens patient safety architecture for citizens dependent on affordable generics via Jan Aushadhi Kendras [1].
Aligns with WHO's drug-safety agenda; IPC aspiring to be WHO Collaborating Centre [5].

Economic

Reinforces credibility of low-cost generics (PMBJP), critical for out-of-pocket health expenditure reduction.

5th National Pharmacovigilance Week inaugurated by IPC, focusing on patient safety and ADR reporting [8].
Three MoUs signed by IPC to bolster medicine safety, quality standards and capacity building (earlier 2025 cycle) [6].
10th Edition of Indian Pharmacopoeia released by Union Health Minister [4].
IPC signed MoUs with Bihar, Maharashtra, Mizoram State Pharmacy Councils [9].
IPC–PMBI and IPC–NIPER Hajipur MoUs signed 24 April 2026 [1][2].

IPC is headquartered at Ghaziabad, under Ministry of Health & Family Welfare (NOT Ministry of Chemicals & Fertilizers) [1].
IPC is the National Coordination Centre for PvPI [3].
ADRMS — India's first indigenous medical product safety database, developed by IPC [3].
PMBI is the implementing agency for PMBJP (Jan Aushadhi) under the Department of Pharmaceuticals.
NIPERs are Institutes of National Importance under the NIPER Act, 1998; Hajipur is in Bihar.
The Indian Pharmacopoeia is the official book of standards for drugs in India; 10th edition released by Union Health Minister [4].
IPC is seeking status as the first WHO Collaborating Centre for Safety of Medicines and Vaccines in SE Asia [5].
Genotoxic impurities flagged in the MoU include nitrosamines [1].
IPC–PMBI MoU covers random batch testing of Jan Aushadhi medicines [1].
National Pharmacovigilance Week — annual event coordinated by IPC; 5th edition recently held [8].

GS-II: Government policies and interventions for development in sectors related to Health; institutions and bodies.
GS-III: Science & Technology; Indigenisation of technology; Pharmaceutical sector and IPR.
Question stems:
"Discuss the role of the Indian Pharmacopoeia Commission in ensuring drug quality and patient safety in India."
"Critically evaluate the Jan Aushadhi Pariyojana's quality assurance mechanisms in the light of recent IPC–PMBI collaboration."
"Pharmacovigilance is the cornerstone of patient safety. Examine India's pharmacovigilance architecture."

PMBJP / Jan Aushadhi Kendras — sister scheme directly impacted.
CDSCO & Drugs Controller General of India (DCGI) — apex drug regulator, distinct from IPC.
Pharmacovigilance Programme of India (PvPI) — IPC's flagship safety programme.
NIPER Act, 1998 — statutory basis for NIPERs.
Drugs and Cosmetics Act, 1940 and New Drugs & Clinical Trials Rules, 2019 — enabling legal framework.
Bulk Drug Parks & PLI scheme for pharma — supply-side complement.
WHO prequalification & SE-Asia drug safety architecture [5].
Ayushman Bharat – PMJAY — demand-side health access.

IPC is under MoHFW, not Ministry of Chemicals & Fertilizers — frequent confusion since PMBI sits under Chemicals & Fertilizers.
IPC ≠ CDSCO; IPC sets standards, CDSCO regulates approval/licensing.
NIPER Hajipur is in Bihar, not Punjab (NIPER Mohali is the original; Hajipur is one of the newer seven).
PMBI is the implementing bureau for PMBJP; PMBJP is the scheme — easy to confuse.
Pharmacovigilance Week is coordinated by IPC, not by CDSCO or ICMR.